SecBot SecBot
SECBOTREPLAY Home › Report › IBRX

IBRX · Q3 revenue +53% YoY

ImmunityBio, Inc. · 8-K filed Nov 9, 2026 at 07:39 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 9, 2026 at 07:39 ET

ImmunityBio reported Q3 2026 net product revenue of $48.7M, up 53% YoY, but missed consensus revenue estimates of $59.2M. The company also announced FDA label expansion for ANKTIVA in BCG-unresponsive NMIBC and positive Phase 2/3 data, while GAAP net loss widened to $184.6M driven by non-cash fair value changes. Cash and marketable securities stood at $334.3M.

  • Q3 2026 net product revenue $48.7M, up 53% YoY from $31.8M
  • First nine months 2026 net product revenue $143.6M, up 92% YoY
  • Revenue miss: actual $48.7M vs consensus $59.2M
  • FDA expanded ANKTIVA label on Oct 14, 2026 to include papillary-only NMIBC

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access